1. |
Molenaar RJ, Van Noorden CJF, Type 2 diabetes and cancer as redox diseases? Lancet 2014;384:853
|
2. |
Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J, Henneman P, Khurshed M, Lenting K, Mul AN, Dimitrakopoulou D, van Drunen CM, Hoebe RA, Radivoyevitch T, Wilmink JW, Maciejewski JP, Vandertop WP, Leenders WP, Bleeker FE, Van Noorden CJ, Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Res 2015;75:4790-4802
|
3. |
Hira VVV, Van Noorden CJF, Carraway HE, MaciejewskiJP, Molenaar RJ, Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. Biochim Biophys Acta 2017;1868:183-198
|
4. |
Krishnaswami V, Van Noorden CJF, Manders EMM, Hoebe RA, Spatially-controlled illumination microscopy. Quart Rev Biophys 2016;49:e19
|
5. |
Van der Wijk AE, Vogels IMC, Van Noorden CJF, Klaassen I, Schlingemann RO, TNFa-induced disruption of the blood-retinal barrier in vitro is regulated by intracellular 3’,5’-cyclic adenosine monophosphate levels. Invest Ophthalmol Vis Sci 2017;58:3496-3505
|